DexCom, Inc. (DXCM) is a San Diego, California-headquartered medical technology company that develops, manufactures, and sells continuous glucose monitoring (CGM) systems. Its operations span research, manufacturing, software, sales, and support, serving people managing diabetes and metabolic health. The company has a market capitalization of $30.95 billion.
Over the past 52 weeks, DexCom’s stock has gained 39.3% as investors grow more confident in accelerating CGM adoption, improving margins, and a broader addressable market beyond insulin-using diabetes patients. It is also up 32.2% over the past six months. The stock reached a 52-week high of $92.59 on Aug. 24, but is down 12% from that level.
Meanwhile, the broader S&P 500 Index ($SPX) has gained 10.1% and marginally over the same periods, respectively, indicating the stock has outperformed the broader market. Compared with its sector, the State Street Health Care Select Sector SPDR ETF (XLV) has increased 22.4% over the past 52 weeks and 28% over the past six months. Therefore, DexCom has outperformed its sector over these periods.
For the third quarter, DexCom reported 11.2% year-over-year (YOY) revenue growth to $1.34 billion, while non-GAAP EPS grew 19.7% YOY to $0.73, surpassing expectations. The strong quarter also saw the advanced rollout of the Dexcom G7 15 Day System in the U.S. Moreover, the system is available in Canada beginning this month for adults 18 years and older, opening up another market prospect. The company also raised its full-year revenue guidance to $5.20 billion-$5.25 billion, indicating 12%-13% growth.
For the current quarter, Wall Street analysts expect DexCom’s diluted EPS to grow 4.4% YOY to $0.71. Moreover, EPS is expected to increase 28.2% annually to $2.68 in fiscal 2026, followed by a 14.9% improvement to $3.08 in fiscal 2027. The company has a solid history of surpassing consensus estimates, topping them in each of the four trailing quarters.
Among the 29 Wall Street analysts covering DexCom’s stock, the consensus is a “Strong Buy.” That’s based on 25 “Strong Buy” ratings, one “Moderate Buy,” and three “Holds.” The ratings configuration has become more bullish over the past two months, with 25 “Strong Buy” ratings, up from 24.
Last month, Barclays analysts maintained an “Overweight” rating on DexCom’s stock and raised the price target from $115 to $120, exhibiting strongly bullish sentiment about the company’s prospects. DexCom’s mean price target of $97.44 indicates a 19.4% upside over current market prices. The Street-high price target of $120 implies a 47% upside.